Member Info for Cliostock

R55, I think sometimes it’s worth putting your head above the parapet when you have something worthwhile to say and in my opinion you have hit the nail on the head there. Great post. One has to make the decision for themself on if the ‘delivery’ is a matter of months away or another 7 years of opportunity cost. I don’t doubt for one minute that Ashman would deliver in months if he could, but I’m equally as sure if he is not capable or things don’t go his way, he’ll let you believe for another 7 years to keep his gravy train rolling. For me, time is up too; if indeed the acquisitions haven’t been accretive, Croda revenues are not allowed to be transparently championed to shareholders by the company, or Superdrug doesn’t have a suitable ROI on that stonking 4.2m raise then the chance to be successful has passed and Stuart Ashman should do the right thing and move on.

Best wishes Nick.

I hope you have realised before your departure that the very thing that seems to have gotten you ostracised, reporting a concern to regulators, is happening left, right and centre as we speak. The irony is not lost on me.

Like you I have never really been one to use the filter feature, but I have had to use it in Mr Humble, Oleric and Obsisian; the self fulfilling ramblings are torturous.

Take care.

Clio

Circles is all any of us are going in sadly Elrico.

Stuart Ashman has closed the motorway!

Gardie. Finally, a post worth reading on here! I’ll look forward with interest to your next post about a reply if one comes.

Better not be Baz!

Net, I would honestly be so much more forgiving to Stuart Ashman if he had a significant number of shares himself. Whilst he is not aligned to shareholders he needs to be held to account, not forgiven for errors with hopes and dreams he’ll do a good job. There is no evidence he has what it takes to make money organically from our science based IP without needing to spend more first. There isn’t a shareholder on this board that couldn’t buy income of 5.3m per annum through acquisitions if they were given a job which included the option of raising millions from the market over several years. SA has made some good moves, but if they are not putting PROFIT on a page at this point in his tenure it’s simply not good enough and SBTX would need better management. Times up. Show us the numbers.

Net, I understand your sentiment behind your comment “DO OUR OWN ADHOC ESTIMATING BASED ON DATA WE CAN SCRAP TOGETHER FROM VARIOUS BITS AND BOBS....” , however I will still continue to mount pressure on Stuart Ashman because if he’d have told me when I met him before investing any serious money that 4 or 5 years down the line I would be working with data I could scrap together from various bits and bobs… I would have run a bloody mile! The fact is what he said was that there was an imminent launch (2021), own brand products would be launching, investors would be given a ‘beauty parade’ explaining all the worldwide cosmetic brands using our IP. Now I’m being treated like I’m somewhere between stupid and unreasonable for wanting some previously promised light financial data over 3 months after the launch. I don’t care for knowing which brands are using it until they launch, I get that. We’ve no own brand products on the horizon, it’s disappointing but SA has been busy, I get that too. And the launch is happening, I just NEED to know it’s not going to be termed a ‘soft launch’ when regulation means the numbers cannot be hidden any longer.

Followed by RNS Tuesday. SBTX is going to raise 4.2m to support the employment of our new social media executive.

The new executive, Joseph Sheedy, wanted to troll for SBTX on an exclusive basis on LSE. Ideally SA wanted to wait until next month but Sheedy made it clear that despite being desperate for exclusivity, he may not want it at all unless it’s done now.

PI’s can of course support the fund raise by buying shares to dilute themselves further at a penny more than the prevailing share price.

It had certainly crossed my mind that the reason for the launch focus on sleep and wellbeing over anti aging was that Croda was not yet fully set up to deal with the production demands of Zenakine if it was enthusiastic about its possibility of being a complete replacement for Matrixyl. It could have even been that the broker note had to go with the ‘official’ line, but that’s delving a bit deep down the conspiracy road and that never works out well for investors…

Net I thought I had explained it clearly but obviously not. Croda have licensed the technology, not Zenakine. Zenakine is the result of Croda’s use of the technology. They can do as they please with it in the cosmetics sector to enhance, create and innovate over the next 20 years. The technology is proprietary to SBTX, if Croda wanted a different lysation method they would have bought it rather than signing the agreement with SBTX. Since the agreement was signed additional enhancements have been found which suggests Skinbiotix is even more of a superior platform than Croda first anticipated. I think Croda buying SBTX is way more likely than SBTX getting to £3 a share.

Net, existing shareholders are already holding heavily, and new ones cannot value the investment opportunity because the company will not release figures on payments it has already received, creating uncertainty which is an uninvestable situation. Ashman should be correcting this but can’t seem to navigate it, which again doesn’t encourage new investors.

Net, I know you haven’t been around as long as others so I’ll give you some leniency, but you must try harder. The Croda deal is a 20 year contract relating to use of the Skinbiotix technology in the cosmetics sector, not Zenakine itself. Other bacteria can be lysated using the technology in house at Croda now, our scientists have done their work. However Croda can only use the technology and any new products they create in the cosmetics sector, unless they make more deals with SBTX, as SBTX are free to do deals with others for use of the lysation technology to be used for absolutely any other application. If SBTX scientists were pushing on with MK2’s and 3’s it’s more reason for Croda to bid, because they should be very worried they would not have a hand in the rewards, as the focus would now be on other applications given the cosmetics field is ticked off our to do list for the next 20 years! Furthermore, SBTX can buy Zenakine at near cost from Croda and use it for any other application at all. I’d argue Croda are somewhat exposed if they want to fully benefit from Skinbiotix and given they move at a glacial speed the only way to secure the full benefits, which arguably only they truly know about, would be to buy SBTX.

Toyin you’re not wrong about the board needing a shakeup. I often wonder how Martin Hunt gets away so lightly in people’s estimations and SA deals with the (justified) grief.

Why does the share chat tab show 41 posts today when I can just see 9 green boxes and OldsCools post? Have some been removed?

I didn’t know Michael Jackson spoke Iranian!

You make a fair point Shychap. If Ashman cannot over come this NDA situation for the good of the shareholders and we are expected to continuously believe that things are going great whilst he takes £30k a month and we lose money every month in a.) SP declines, b.) SP stagnates and inflation continues, c.) we get diluted, d.) opportunity cost on our invested money; then Ashman and the rest of the board are fundamentally no good to us. I agree with your timescale of a month, before we get the information we were promised; if not I intend to go full activist. We are getting p155ed on and told its to cool us down. And of course if the details are being hidden because they are not flattering then after Mr Ashman’s rhetoric, another reason he would need to go on the double. I don’t necessarily think that is, or needs to be the case, but I’ve personally been strung along for long enough now, I’ve had my fill of that, I simply want to be able to calculate the true value of my investment so I know if I need to stay or go.

I was also pretty appalled to see what was a total one sided hit job on Belgrano be published on Josh’s Substack. I’ve been speaking to Belgrano for around 5 years on here and always found the conversation to be two way and reasonable. If some think they have noticed a habit of dancing between stocks and encouraging others to follow, it’s up to them if they wish to call it out on the board but that Substack article was overkill by an anonymous figure with no right to reply for Belgrano. I’m sure i’ve read all of Bel’s input on LSE and ADVFN and never thought of selling any SBTX nor buying into INSG.

Elric, for what it’s worth when I read Belgrano’s post I didn’t think of it as one that damaged your reputation or even attempted to, it just read as a frustrated man telling his side. Josh made some great points on your Substack articles gaining some likes and you shared his first article and I think for that reason he has enjoyed the eyes of many of your supporters for that distasteful article about Belgrano. It says a lot that you tried to get it taken down for Bel and even more about Josh’s ego if he refused. The follow up articles were analysis paralysis anyway which detracted from any points that were trying to be made.

I don’t think anyone comes out of this looking good which might be a stark reminder to all to stick to talking about companies!

Thecontender, that’s all we really need. Revenues received to date. It can be one sentence for all I care. I also don’t care if it’s £50k or less. It’s about the income becoming tangible instead of implied.

The broker note will deal with the future outlook and the Superdrug IMC will let us know more about the future of that deal and the allocation of the £4.1m.

PGlancy, do you mean the discussion about the market dynamics around the recent SP? If so I have read that and yes enjoyed it very much. If not, I can’t see anything else, but Substack is awful for going back to a thread when you have already read part of it and want to check for new comments.

And yes Oleric, Josh is clearly a very bright chap. Unless he is on there trolling a Nordic guy called Hojs.

Agreed, seeing their current offering and the costs and side affects I can see why Superdrug wanted the exclusivity as it would be a huge USP for them. Also, I was first concerned about going into only 25% of the store portfolio initially, as I was thinking that Superdrug would not do any kind of national advertising if the product wasn’t available in most stores to start with, however if it’s available online that satisfies me that it would be beneficial for them to do an awareness campaign.